Sulbutiamine

Sulbutiamine is a synthetic dimer of two modified thiamine (vitamin B1) molecules joined by a disulfide bond. Developed in Japan in the 1960s to address thiamine deficiency more effectively than standard thiamine supplements, its increased lipophilicity allows it to cross the blood-brain barrier far more efficiently. Once in the brain, sulbutiamine raises thiamine and thiamine phosphate ester concentrations, which are essential cofactors in energy metabolism and neurotransmitter synthesis. Research indicates that sulbutiamine modulates dopaminergic, glutamatergic, and cholinergic pathways. It is marketed as a prescription drug (Arcalion) in France for treating asthenia (functional fatigue) and is sold as an over-the-counter supplement in many other countries. Clinical evidence, while promising, remains limited and primarily comes from small trials.